Using genomic profiling for understanding and improving response to smoking cessation treatment

Area of Science:

• Genetics and Genomics
• Public Health
• Behavioral Science

Background:

• Smoking behaviors and related illnesses are significant public health concerns.
• Genomic research has identified specific genetic variations influencing smoking habits and disease susceptibility.
• Translating these discoveries into clinical practice requires careful consideration of implementation strategies.

Purpose of the Study:

• To review the implementation of genomic discoveries for smoking cessation and prevention.
• To highlight the role of genetic variations in smoking behaviors and related diseases.
• To discuss the clinical utility and potential healthcare disparities associated with genomic profiling.

Main Methods:

• Literature review of large-scale genomic studies.
• Analysis of established genetic variations (e.g., CHRNA5, CYP2A6) and their impact.
• Examination of evidence for clinical validity and utility.

Main Results:

• Genomic variations, particularly in CHRNA5 and CYP2A6, are strongly associated with smoking heaviness and cessation.
• These genes are implicated in lung cancer and chronic obstructive pulmonary disease.
• Growing evidence supports the clinical utility of these genetic markers for risk stratification.

Conclusions:

• Genomic profiling holds promise for enhancing smoking cessation and prevention strategies.
• Readiness for implementation of genomic profiling is increasing.
• Addressing potential healthcare disparities and ensuring equity is paramount for successful translation of genomic findings.